Jonathan Frandsen1, Dustin Boothe1, David K Gaffney1, Brent D Wilson1, Shane Lloyd1. 1. 1 Radiation Oncology Department, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA ; 2 Division of Cardiology, University of Utah, University Hospital, Salt Lake City, UT 84112, USA.
Abstract
OBJECTIVE: To evaluate the risk of heart disease related death (HDRD) following radiation therapy (RT) for esophageal cancer (EC). METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, two cohorts of patients with EC were created: (I) patients who received RT with their initial therapy; and (II) those who did not. Heart disease specific survival (HDSS) was analyzed using Kaplan-Meier methods. Cox proportional-hazards regression methods were used for univariate and multivariate analyses. RESULTS: We identified 40,778 patients with EC. A total of 26,377 patients received RT and 14,401 did not. HDSS analysis revealed increased risk of HDRD in those receiving RT (P<0.05), with an absolute risk of HDRD of 2.8%, 5.3% and 9.4% at 5-, 10- and 20-year, respectively. Log rank test of HDSS revealed the risk of HDRD became significant at 8 months (P<0.05). The following were associated with HDRD: RT, age, race, stage at presentation, time period of diagnosis, and known comorbid condition keeping one from esophagectomy. On multivariate analysis, RT remained predictive of HDRD [hazard ratio (HR) 1.46, P<0.05]. When considering only candidates for definitive therapy, RT remained predictive of HDRD on univariate (HR 1.53, P<0.0001) and multivariate (HR 1.62, P<0.0001) analyses. CONCLUSIONS: The use of RT leads to increased risk of HDRD that is detectable as early as eight months from diagnosis. More research is needed to define optimal dose volume parameters to prevent cardiac death. Consideration should be given to this risk in relation to prognosis and the expected benefits of RT.
OBJECTIVE: To evaluate the risk of heart disease related death (HDRD) following radiation therapy (RT) for esophageal cancer (EC). METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, two cohorts of patients with EC were created: (I) patients who received RT with their initial therapy; and (II) those who did not. Heart disease specific survival (HDSS) was analyzed using Kaplan-Meier methods. Cox proportional-hazards regression methods were used for univariate and multivariate analyses. RESULTS: We identified 40,778 patients with EC. A total of 26,377 patients received RT and 14,401 did not. HDSS analysis revealed increased risk of HDRD in those receiving RT (P<0.05), with an absolute risk of HDRD of 2.8%, 5.3% and 9.4% at 5-, 10- and 20-year, respectively. Log rank test of HDSS revealed the risk of HDRD became significant at 8 months (P<0.05). The following were associated with HDRD: RT, age, race, stage at presentation, time period of diagnosis, and known comorbid condition keeping one from esophagectomy. On multivariate analysis, RT remained predictive of HDRD [hazard ratio (HR) 1.46, P<0.05]. When considering only candidates for definitive therapy, RT remained predictive of HDRD on univariate (HR 1.53, P<0.0001) and multivariate (HR 1.62, P<0.0001) analyses. CONCLUSIONS: The use of RT leads to increased risk of HDRD that is detectable as early as eight months from diagnosis. More research is needed to define optimal dose volume parameters to prevent cardiac death. Consideration should be given to this risk in relation to prognosis and the expected benefits of RT.
Entities:
Keywords:
Esophageal cancer (EC); heart disease; radiation therapy (RT)
Authors: Thomas P Kole; Osarhieme Aghayere; Jason Kwah; Ellen D Yorke; Karyn A Goodman Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-26 Impact factor: 7.038
Authors: Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: T H La; A Y Minn; Z Su; G A Fisher; J M Ford; P Kunz; K A Goodman; A C Koong; D T Chang Journal: Dis Esophagus Date: 2009-08-28 Impact factor: 3.429
Authors: Yi-Jen Chen; An Liu; Chunhui Han; Peter T Tsai; Timothy E Schultheiss; Richard D Pezner; Nilesh Vora; Dean Lim; Stephen Shibata; Kemp H Kernstine; Jeffrey Y C Wong Journal: Med Dosim Date: 2007 Impact factor: 1.482
Authors: Steven H Lin; Lu Wang; Bevan Myles; Peter F Thall; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-03 Impact factor: 7.038
Authors: Jacob S Witt; Justin C Jagodinsky; Yifei Liu; Poonam Yadav; Aleksandra Kuczmarska-Haas; Menggang Yu; James D Maloney; Mark A Ritter; Michael F Bassetti; Andrew M Baschnagel Journal: Am J Clin Oncol Date: 2019-08 Impact factor: 2.339
Authors: Ali Kirresh; Laura White; Adam Mitchell; Shahzaib Ahmad; Bernard Obika; Sarah Davis; Mahmood Ahmad; Luciano Candilio Journal: Clin Med (Lond) Date: 2022-05 Impact factor: 5.410
Authors: Milan Vošmik; Miroslav Hodek; David Buka; Petra Sýkorová; Jakub Grepl; Petr Paluska; Simona Paulíková; Igor Sirák Journal: Rep Pract Oncol Radiother Date: 2020-02-25
Authors: Reith R Sarkar; Ahmadreza Hatamipour; Neil Panjwani; P Travis Courtney; Daniel R Cherry; Mia A Salans; Anthony T Yip; Brent S Rose; Daniel R Simpson; Matthew P Banegas; James D Murphy Journal: Am J Clin Oncol Date: 2021-06-01 Impact factor: 2.787
Authors: Y Jessica Huang; Alexis Harrison; Vikren Sarkar; Prema Rassiah-Szegedi; Hui Zhao; Martin Szegedi; Long Huang; Brent Wilson; David K Gaffney; Bill J Salter Journal: Adv Radiat Oncol Date: 2016-04-26
Authors: Meghan W Macomber; Stephen R Bowen; Olga Gopan; Rosanna Yeung; Smith Apisarnthanarax; Jing Zeng; Shilpen Patel Journal: Cureus Date: 2018-03-27
Authors: Laila Gharzai; Vivek Verma; Kyle A Denniston; Abhijeet R Bhirud; Nathan R Bennion; Chi Lin Journal: PLoS One Date: 2016-07-18 Impact factor: 3.240